CA2054190A1 - Proteines pour la lutte contre la maladie et la protection du betail paturant contre les tiques - Google Patents
Proteines pour la lutte contre la maladie et la protection du betail paturant contre les tiquesInfo
- Publication number
- CA2054190A1 CA2054190A1 CA002054190A CA2054190A CA2054190A1 CA 2054190 A1 CA2054190 A1 CA 2054190A1 CA 002054190 A CA002054190 A CA 002054190A CA 2054190 A CA2054190 A CA 2054190A CA 2054190 A1 CA2054190 A1 CA 2054190A1
- Authority
- CA
- Canada
- Prior art keywords
- protein
- ticks
- protecting
- grazing cattle
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 49
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 48
- 241000238876 Acari Species 0.000 title claims abstract description 14
- 241000283690 Bos taurus Species 0.000 title claims abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 4
- 238000009304 pastoral farming Methods 0.000 title claims abstract description 4
- 201000010099 disease Diseases 0.000 title claims abstract 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 8
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 claims description 5
- 238000010353 genetic engineering Methods 0.000 claims description 3
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 230000003053 immunization Effects 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 239000000306 component Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001376 precipitating effect Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 23
- 239000011780 sodium chloride Substances 0.000 description 12
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 description 5
- 229940122388 Thrombin inhibitor Drugs 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 239000003868 thrombin inhibitor Substances 0.000 description 5
- 239000000872 buffer Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000007625 Hirudins Human genes 0.000 description 2
- 108010007267 Hirudins Proteins 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 2
- 229940006607 hirudin Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000004153 renaturation Methods 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 229960004319 trichloroacetic acid Drugs 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 108091028026 C-DNA Proteins 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010014513 Embolism arterial Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000545744 Hirudinea Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000238887 Ornithodoros Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 239000012614 Q-Sepharose Substances 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000006167 equilibration buffer Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012847 fine chemical Substances 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- PGLTVOMIXTUURA-UHFFFAOYSA-N iodoacetamide Chemical compound NC(=O)CI PGLTVOMIXTUURA-UHFFFAOYSA-N 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 229940070376 protein Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DEP3931839.7 | 1989-09-23 | ||
| DE3931839A DE3931839A1 (de) | 1989-09-23 | 1989-09-23 | Neue proteine und ihre herstellung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2054190A1 true CA2054190A1 (fr) | 1991-03-24 |
Family
ID=6390068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002054190A Abandoned CA2054190A1 (fr) | 1989-09-23 | 1990-09-18 | Proteines pour la lutte contre la maladie et la protection du betail paturant contre les tiques |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0493494A1 (fr) |
| JP (1) | JPH05500809A (fr) |
| CA (1) | CA2054190A1 (fr) |
| DE (1) | DE3931839A1 (fr) |
| WO (1) | WO1991004275A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5523287A (en) * | 1991-11-06 | 1996-06-04 | Basf Aktiengesellschaft | Thrombin-inhibitory protein from assassin bugs |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4134814A1 (de) * | 1991-10-22 | 1993-04-29 | Basf Ag | Neues thrombininhibitorisches protein aus zecken |
| DE4136087A1 (de) * | 1991-10-31 | 1993-05-06 | Basf Ag, 6700 Ludwigshafen, De | Neues thrombininhibitorisches protein aus zecken |
| US5321010A (en) * | 1991-12-10 | 1994-06-14 | Merck & Co., Inc. | Proteins for inhibiting adhesion of platelets to collagen |
| DK0677107T3 (da) * | 1992-12-04 | 1998-03-16 | Schering Ag | Thrombininhibitor fra protostomispyt |
| CN115553287B (zh) * | 2022-10-27 | 2023-08-08 | 北京标驰泽惠生物科技有限公司 | 一种蜱虫保存液及其制备方法和应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZM5186A1 (en) * | 1985-07-03 | 1986-12-29 | Coopers Animal Health | Tick vaccine |
| DE3819078A1 (de) * | 1988-06-04 | 1989-12-07 | Hoechst Ag | Amblyommin, ein neuer wirkstoff fuer die antikoagulationstherapie |
-
1989
- 1989-09-23 DE DE3931839A patent/DE3931839A1/de not_active Withdrawn
-
1990
- 1990-09-18 WO PCT/EP1990/001578 patent/WO1991004275A1/fr not_active Application Discontinuation
- 1990-09-18 CA CA002054190A patent/CA2054190A1/fr not_active Abandoned
- 1990-09-18 EP EP90914720A patent/EP0493494A1/fr not_active Withdrawn
- 1990-09-18 JP JP2513587A patent/JPH05500809A/ja active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5523287A (en) * | 1991-11-06 | 1996-06-04 | Basf Aktiengesellschaft | Thrombin-inhibitory protein from assassin bugs |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0493494A1 (fr) | 1992-07-08 |
| JPH05500809A (ja) | 1993-02-18 |
| DE3931839A1 (de) | 1991-04-04 |
| WO1991004275A1 (fr) | 1991-04-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS60136597A (ja) | デスルフアトヒルジン、その製造及びそれを含む製薬組成物 | |
| JP2007084554A (ja) | 新規蛋白質及びこれを使用した薬剤の製法 | |
| JPH0720992B2 (ja) | ヒルディン−ｐａとその誘導体、それらの製造法と応用 | |
| Odani et al. | Purification and complete amino acid sequence of novel β2-microglobulin | |
| JPH11514334A (ja) | タンパク質の可溶化、精製、および再生の方法 | |
| van Damme et al. | The monomeric and dimeric mannose-binding proteins from the Orchidaceae species Listera ovata and Epipactis helleborine: sequence homologies and differences in biological activities | |
| JPH04502907A (ja) | 抗トロンビン | |
| Fernley et al. | Purification and characterization of a high-M r carbonic anhydrase from sheep parotid gland | |
| CA2054190A1 (fr) | Proteines pour la lutte contre la maladie et la protection du betail paturant contre les tiques | |
| JP2972328B2 (ja) | ヒトエラスターゼインヒビター | |
| Bassuk et al. | Expression of biologically active human SPARC inEscherichia coli | |
| WO2003003835A1 (fr) | Procede de controle du rendement et de la purete d'un inhibiteur ii de la proteinase au cours de l'extraction | |
| Qian et al. | Separation and characterization of two polypeptide chains from the 7S cross-linking domain of basement-membrane (type IV) collagen | |
| JPH01308300A (ja) | ヘパリン結合性脳ミトゲン | |
| US6436396B1 (en) | Polypeptides having L-asparaginase activity | |
| EP0612349B1 (fr) | Nouvelle proteine inhibitrice de la trombine isolee dans les reduves | |
| US5585350A (en) | Thrombin-inhibitory protein from ticks | |
| JPH0965879A (ja) | 新規血栓溶解酵素とその製造方法 | |
| EP0609242B1 (fr) | Nouvelle proteine inhibitrice de la thrombine provenant de tiques | |
| JP3251545B2 (ja) | 精子運動能促進性高分子タンパク質 | |
| JPH1080281A (ja) | 新規蛋白質及びその製造方法 | |
| Grogan et al. | Studies on Fractionation of Saline-Soluble Nucleolar Proteins on Diethylaminoethylcellulose | |
| JPH04279598A (ja) | 血清カルシウム降下因子 | |
| US5827731A (en) | Thrombin-inhibitory protein from ticks | |
| Damme et al. | The monomeric and dimeric mannose-binding proteins from the Orchidaceae speciesListera ovata andEpipactis helleborine: sequence homologies and differences in biological activities |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |